Thalidomide stimulates splenic IgM antibody response and cytotoxic T lymphocyte activity and alters leukocyte subpopulation numbers in female B6C3F1 mice

Toxicology and Applied Pharmacology

Volumn 165, Issue 3, 2000, Pages 237-244

  Karrow, N A ^a   McCay, J A ^a   Brown, R D ^a   Musgrove, D L ^a   Pettit, D A ^a   Munson, A E ^a   Germolec, D R ^b   White Jr , K L ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

B6C3F1 mice; Immunomodulation; Thalidomide

Indexed keywords

CD8 ANTIGEN; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN M ANTIBODY; THALIDOMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; IMMUNOMODULATION; LYMPHOCYTE SUBPOPULATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; SPLEEN CELL; SUPPRESSOR CELL;

ANIMALIA; MURINAE;

EID: 0034659426     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.2000.8939     Document Type: Article

References (37)

1. Arala-Chives M., Vilanova M., Ribeiro A., Pinto J. I. Immunostimulatory effect of thalidomide in normal C57BL/6 mice is compatible with stimulation of a highly connected central immune system. Scand. J. Immunol. 40:1994;535-542.
2. Ball S. C., Sepkowitz A. K. A., Jacobs J. L. Thalidomide for treatment of oral aphthous ulcers in patients with human immunodefiency virus: Case report and review. Am. J. Gastroenterol. 92:1997;169-170.
3. Bartlett M. S. Sub-sampling for attributes. J. Roy. Stat. Soc. Suppl. 4:1937;131.
4. Calderon P., Anzilotti M., Phelps R. Thalidomide in dermatology. New indications for an old drug. Int. J. Dermatol. 36:1997;881-887.
5. 1. J. Immunol. 163:1999;380-386.
6. Dunnett C. W. A multiple comparison procedure for comparing several treatments with a control. J. Am. Stat. Assoc. 47:1955;583.
7. Gately M. K., Desai B. B., Wolitzky A. G., Quinn P. M., Dwyer C. M., Podlaski F. J., Familletti P. C., Sinigaglia F., Chizonnite R., Gubler U., Stern A. S. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J. Immunol. 147:1991;874-882.
8. Gross A. J., Clark V. A. Gehan-Wilcoxon test. Gross A. J., Clark V. A. Survival Distribution: Reliability Applications in Biomedical Sciences. 1975;John Wiley and Sons, New York.
9. Haslett P. A. Anticytokine approaches to the treatment of anorexia and cachexia. Semin. Oncol. 25:1998;53-57.
10. Haslett P. A., Corral L. G., Albert M., Kaplan G. Thalidomide costimulates primary human T lymphocytes preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J. Exp. Med. 187:1998;1885-1892.
11. Haslett P., Hempstead M., Seidman C., Diakun J., Vasquez D., Freedman V. H., Kaplan G. The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with human immunodeficiency virus. AIDS Res. Hum. Retroviruses. 13:1997;1047-1053.
12. Hollander M., Wolfe D. A. Jonckheere's Test: Non-Parametric Statistics Methods. 1975;John Wiley and Sons, New York.
13. Jerne N. K., Nordin A. A. Plaque formation in agar by single antibody-producing cells. Science. 140:1963.
14. Kaplan G. Cytokine regulation of disease progression in leprosy and tuberculosis. Immunobiology. 191:1994;564-568.
15. Klausner J. D., Kaplan G., Haslett P. A. Thalidomide in toxic epidermal necrolysis. Lancet. 353:1999;324.
16. Kos F. J., Engleman E. G. Immune regulation: A critical link between NK cells and CTLs. Immunol. Today. 17:1996;174-176.
17. Kruskal W. H., Wallis W. A. Use of ranks in one-criterion variance analysis. J. Am. Stat. Assoc. 47:1952;583.
18. Luster M. I., Munson A. E., Thomas P. T., Holsapple M. P., Fenters J. D., White K. L. Jr., Lauer L. D., Germolec D. R., Rosenthal G. J., Dean J. H. Development of a testing battery to assess chemical-induced immunotoxicity: National Toxicology Program's guidelines for immunotoxocity evaluation in mice. Fundam. Appl. Toxicol. 10:1988;2-19.
19. Makonkawkeyoon S., Limson-Pobre R. N., Moreira A. L., Schauf V., Kaplan G. Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA. 90:1993;5974-5978.
20. Mascher B., Schlenke P., Seyfarth M. Expression and kinetics of cytokines determined by intracellular staining using flow cytometry. J. Immunol. Methods. 223:1999;115-121.
21. Moller D. R., Wysicka M., Greenlee B. M, Ma X., Wahl L., Flockhart D. A., Trinchieri G., Karp C. L. Inhibition of IL-12 production by thalidomide. J. Immunol. 159:1997;5157-5161.
22. Moreira A. L., Tsenova L., Berkova O., Wang J., Laochumroonvorapong P., Freeman S., Freedman V. H., Kaplan G. Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosis. Tubercle Lung Dis. 78:1997;47-55.
23. Oliveira R. B., Moraes M. O., Oliveira E. B., Sarno E. N., Nery J. A., Sampaio E. P. Neutrophils isolated from leprosy patients release TNF-α and exhibit accelerated apoptosis in vitro. J. Leukocyte Biol. 65:1999;364-370.
24. Reynolds C. W., Herberman R. B. In vitro augmentation of natural killer (NK) cell activity. J. Immunol. 126:1981.
25. Rowland T. L., McHugh S. M., Deighton J., Dearman R. J., Ewan P. W., Kimber I. Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells. Immunopharmacology. 40:1998;11-20.
26. Shannon E. J., Sandoval F., Krahenbuhl J. L. Hydrolysis of thalidomide abrogates its ability to enhance mononuclear cell synthesis of IL-2 as well as its ability to suppress the synthesis of TNF-α Immunopharmacology. 36:1997a;9-15.
27. Shannon E. J., Morales M. J., Sandoval F. Immunomodulatory assays to study structure-activity relationships of thalidomide. Immunopharmacology. 35:1997b;203-212.
28. Sheskin J. Thalidomide in the therapy of lepra reactions. Clin. Pharmacol. Ther. 6:1965;303-306.
29. Slifka M. K., Ahmed R. Long-lived plasma cells: A mechanism for maintaining persistent antibody production. Curr. Opin. Immunol. 10:1998;252-258.
30. Sokal R. R., Rohlf F. J. Biometry. 1981;Freeman, San Fransisco.
31. Tavares J. L., Wangoo A., Dilworth P., Marshall B., Kotecha S., Shaw R. J. Thalidomide reduces tumour necrosis factor-α production by human alveolar macrophages. Respir. Med. 91:1997;31-39.
32. Temple L., Kawabata T. T., Munson A. E., White K. L. Jr. Comparison of ELISA and plaque-forming cell assay for measuring the humoral immune response to sRBC in animals treated with benzo(a)pyrene or cyclophosphamide. Fundam. Appl. Toxicol. 21:1993;412-419.
33. Tseng S., Pak G., Washenik K., Pomeranz M. K., Shupack J. L. Re-discovering thalidomide: A review of its mechanism of action, side effects, and potential uses. J. Am. Acad. Dermatol. 35:1996;969-979.
34. Vilanova M., Ribeiro A., Carneiro J., Arala-Chives M. II. The effects of thalidomide treatment on autoimmune-prone NZB and MRL mice are consistent with stimulation of the central immune system. Scand. J. Immunol. 40:1994;543-548.
35. Wilson K. V. A distribution free test of analysis of variance hypothesis. Psychol. Bull. 53:1956;96-101.
36. Zhu J., Deng G. M., Diab A., Zwingenberger K., Bakhiet M., Link H. Thalidomide prolongs experimental autoimmune neutitis in Lewis rats. Scand. J. Immunol. 48:1998;397-402.
37. Zwingenberger K., Wnendt S. Immunomodulation by thalidomide: Systematic review of the literature and of unpublished observations. J. Inflam. 46:1996;177-211.